We use cookies to optimise this website and continuously update it according to your needs. Please click on "Configure" for detailed information on the use of cookies on this website. If you click "Yes, I agree", cookies will be activated. If you do not want cookies to be activated, you can adjust your settings by clicking on "Configure". The settings can be changed at any time under "Cookies".
STOCKHOLM, October 11, 2017 – Michigan-based McLaren Health Care and Elekta (EKTA-B.ST) have mutually agreed to terminate their business agreement from December 2013. McLaren Health Care and Elekta will continue their business relationship but on a smaller scale.
In accordance with its process for constant review of backlog, Elekta has therefore determined to reduce USD 72 million of the backlog, to be reported in Q2 fiscal year 2017/18. There will be no material effect on Elekta’s results.
# # #
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm www.elekta.com
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242,
E-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communications, Elekta AB
Tel: +46 722 215 017,
E-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time